We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Dynavax Reports Phase 1B Safety and Immunogenicity Results for Hepatitis B Therapy Candidate

News   Dec 24, 2010

 
Dynavax Reports Phase 1B Safety and Immunogenicity Results for Hepatitis B Therapy Candidate
 
 
 

RELATED ARTICLES

Tuberculosis Tests are Inadequate, Better Options Identified

News

Rapid blood tests used by the NHS are unable to rule out tuberculosis (TB) and should be replaced with a new, more accurate test, a study has found.

READ MORE

Cellular Protein a Target for Zika Control

News

A cellular protein that interacts with invading viruses appears to help enable the infection process of the Zika virus, according to researchers who suggest this protein could be a key target in developing new therapies to prevent or treat Zika virus infection.

READ MORE

Poo Transplant Shows Promise in Prelim Study for Ulcerative Colitis

News

Anaerobically prepared fecal microbiota transplantation improved remission rates in people with moderately active ulcerative colitis at 8 weeks. Further research is needed to assess longer-term efficacy and safety.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE